Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (648)	6/9/2004 9:12:32 AM
From: Icebrg	Read Replies (2) \| Respond to of 1022

ICOS and Raven Biotechnologies Enter Exclusive Collaboration for Antibody Therapeutics Wednesday June 9, 8:30 am ET BOTHELL, Wash. & SOUTH SAN FRANCISCO--(BUSINESS WIRE)--June 9, 2004--ICOS Corporation (Nasdaq:ICOS - News) and Raven biotechnologies, inc. today announced that they have entered into an agreement that provides ICOS with an exclusive option to license five of Raven's monoclonal antibody candidates for potential therapeutic applications, including cancer therapies. Under the agreement, Raven will receive an upfront payment and potential future milestone and royalty payments. Further terms of the agreement were not disclosed. "We have been impressed with the discoveries that Raven has made using their proprietary technologies," stated W. Michael Gallatin, Ph.D., ICOS Vice President and Scientific Director. "This collaboration expands ICOS' commitment to the development of biological drug candidates. In addition, this agreement enables ICOS to initiate our third preclinical program in oncology, while leveraging the oncology expertise from our programs in cell cycle checkpoints and lipid kinases." Jennie P. Mather, Ph.D., Founder, President and CEO of Raven stated, "Raven is pleased to add ICOS as a collaborator in developing antibodies derived from our innovative cell biology-based approach to discovering novel targets and monoclonal antibodies. ICOS' expertise in the development of novel therapeutics, as well as in biologics manufacturing, makes them a unique strategic fit." Mather added, "This agreement is another step toward Raven's goal of making many new anticancer therapeutic antibodies available to patients as rapidly as possible. We will continue partnering with committed, industry-leading companies while at the same time, independently moving Raven's lead antibodies into the clinic."